Aquestive Licenses Libervant To Eton For $10 Million Upfront As Quarterly Revenue Falls 41%

The drugmaker's cash fell to $90.3 million as lower Suboxone orders cut third-quarter revenue to $7.6 million.

Share
Aquestive Licenses Libervant To Eton For $10 Million Upfront As Quarterly Revenue Falls 41%

Aquestive Therapeutics, which makes dissolvable oral-film medicines, licensed U.S. rights to its seizure drug Libervant to Eton Pharmaceuticals for a $10 million upfront payment, according to its quarterly report filed Tuesday. The same report shows third-quarter revenue down 41% to $7.6 million as Suboxone orders dropped.

Terms of the Eton deal

Under the October 13 agreement, Eton takes on U.S. commercialization of Libervant, subject to regulatory approvals. Aquestive can earn up to $47.5 million in milestones and mid-teens royalties on net sales.

Milestones start with $10 million at first U.S. commercial sale, which drops to $5 million without full approval for ages 2 to 5. Sales-based payments account for up to $35 million of the total.

Aquestive remains the exclusive manufacturer under a 20-year supply deal. After that, it extends automatically in three-year increments unless a party objects two or more years ahead of a term's end.

A product it cannot yet sell

Libervant has tentative FDA approval for patients 2 to 5 and 12 and older, and is not available for U.S. market access. Final approval for ages 12 and up depends on Valtoco's orphan drug exclusivity expiring on January 10, 2027, and FDA action, with a goal date of March 23, 2027. A separate application for ages 6 to 11 has a goal date of March 29, 2027.

The filing says the company's U.S. Libervant sales ended in April 2025 after a court case challenging the FDA's approval. Oral argument in the appeal is scheduled for December 2026.

Suboxone orders drop, cash shrinks

Revenue fell to $7.557 million from $12.807 million a year earlier. Manufacture and supply revenue dropped 42%, mainly on about $5.6 million less Suboxone revenue, partly offset by about $1.1 million more from Ondif. The prior quarter's report had credited higher Suboxone revenue for growth.

For the first nine months, revenue rose 14% to $35.8 million, helped by a one-time $5 million Zevra royalty.

The net loss was $16.5 million, against $15.4 million a year earlier. Cash stood at $90.3 million on September 30, down from $98.5 million at the end of June, before the Eton payment. The accumulated deficit reached $494.4 million.

Anaphylm remains the main bet

The company resubmitted its epinephrine film Anaphylm to the FDA on September 16, and the FDA set a goal date of March 16, 2027, according to the earnings release. It kept full-year revenue guidance at $46 million to $50 million. An investor call is set for November 4.

The FDA's Anaphylm decision is due by March 16, 2027, with Libervant's final decisions days later.

Sources

More on Aquestive Therapeutics

All Aquestive Therapeutics (AQST) coverage →